Evrogen

Executive Summary

Evrogen is a Russian biotechnology company established in 2001 that develops and commercializes innovative tools for life science research, with a primary focus on fluorescent proteins, expression vectors for subcellular labeling, and specialized molecular biology services such as cDNA normalization and library construction. Serving the global research community, its products are widely used in cell biology, genomics, and imaging applications. Despite being a niche player, the company has built a reputation for high-quality reagents and has a loyal customer base among academic and industrial researchers. However, its operations are constrained by geopolitical risks and limited access to international markets, which may hinder its growth compared to competitors in the US and Europe. Evrogen remains privately held with no disclosed funding, and its valuation and revenue are not publicly available, making it difficult to assess its financial performance. The company's future prospects depend on its ability to expand its product portfolio, forge strategic partnerships, and navigate sanctions and trade barriers. While its technology is well-regarded, the lack of transparency and exposure to Russian market dynamics present significant uncertainties for investors.

Upcoming Catalysts (preview)

• TBDLaunch of new fluorescent protein variants for advanced imaging70% success
• TBDExpansion of distribution partnerships in Asia or Middle East50% success
• TBDIntroduction of CRISPR-related gene editing tools30% success